Oral salmon calcitonin pharmacology in osteoporosis

Expert Opinion on Biological Therapy

Volumn 10, Issue 11, 2010, Pages 1617-1629

  Henriksen, Kim ^a   Bay Jensen, Anne Christine ^a   Christiansen, Claus ^a   Karsdal, Morten Asser ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Coupling; Oral formulation; Osteoclasts; Osteoporosis; Safety; Salmon calcitonin

Indexed keywords

DENOSUMAB; ELIGEN; ODANACATIB; PLACEBO; SALCATONIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; HYPERSENSITIVITY; NAUSEA; OSTEOPOROSIS; REVIEW;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; AGED; AMINO ACIDS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCITONIN; CIRCADIAN RHYTHM; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; FEMALE; HUMANS; MIDDLE AGED; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RECEPTORS, CALCITONIN;

EID: 77958486894     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.526104     Document Type: Review

References (126)

1. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-2261
2. Karsdal MA, Martin TJ, Bollerslev J, et al. Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 2007;22:487-494
3. Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA. Local communication on and within bone controls bone remodeling. Bone 2009;44:1026-1033
4. Copp DH, Cameron EC, Cheney BA, et al. Evidence for calcitonin - a new hormone from the parathyroid that lowers blood calcium. Endocrinology 1962;70:638-649
5. Kumar MA, Foster GV, MacIntyre I. Further evidence for calcitonin. A rapid-acting hormone which lowers plasma-calcium. Lancet 1963;35:480-482
6. Sexton PM, Findlay DM, Martin TJ. Calcitonin. Curr Med Chem 1999;6:1067-1093
7. Deftos LJ. Calcitonin. 6th edition. 2006. p. 115-117
8. Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 1983;57:819-824
9. Bagger YZ, Tanko LB, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005;37:425-430
10. Manicourt DH, Azria M, Mindeholm L, et al. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006;54:3205-3211
11. Sondergaard BC, Oestergaard S, Christiansen C, et al. The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum 2007;56:2674-2678
12. Van den Mooter G. Colon drug delivery. Expert Opin Drug Deliv 2006;3:111-125
13. Shareef MA, Khar RK, Ahuja A, et al. Colonic drug delivery: an updated review. AAPS PharmSci 2003;5:E17
14. Wiktor-Jedrzejczak W, Urbanowska E, Aukerman SL, et al. Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor. Exp Hematol 1991;19:1049-1054
15. Yamamoto M, Tachikawa S, Maeno H. Effects of porcine calcitonin on behavioral and electrophysiological responses elicited by electrical stimulation of the tooth pulp in rabbits. Pharmacology 1982;24:337-345
16. Lee YH, Sinko PJ. Oral delivery of salmon calcitonin. Adv Drug Deliv Rev 2000;42:225-238
17. Torres-Lugo M, Peppas NA. Transmucosal delivery systems for calcitonin: a review. Biomaterials 2000;21:1191-1196
18. Buclin T, Cosma RM, Burckhardt P, et al. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 2002;17:1478-1485
19. Sakuma S, Suzuki N, Sudo R, et al. Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int J Pharm 2002;239:185-195
20. Guggi D, Kast CE, Bernkop-Schnurch A. In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm Res 2003;20:1989-1994
21. Wang J, Chow D, Heiati H, Shen WC. Reversible lipidization for the oral delivery of salmon calcitonin. J Control Release 2003;88:369-380
22. Tanko LB, Bagger YZ, Alexandersen P, et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 2004;19:1531-1538
23. Bernkop-Schnurch A, Hoffer MH, Kafedjiiski K. Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin Drug Deliv 2004;1:87-98
24. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. pH-sensitive microsphere delivery increases oral bioavailability of calcitonin. J Control Release 2004;98:1-9
25. Mehta NM, Malootian A, Gilligan JP. Calcitonin for osteoporosis and bone pain. Curr Pharm Des 2003;9:2659-2676
26. Leone-Bay A, Santiago N, Achan D, et al. N-acylated alpha-amino acids as novel oral delivery agents for proteins. J Med Chem 1995;38:4263-4269
27. Leone-Bay A, McInnes C, Wang N, et al. Microsphere formation in a series of derivatized alpha-amino acids: properties, molecular modeling, and oral delivery of salmon calcitonin. J Med Chem 1995;38:4257-4262
28. Malkov D, Angelo R, Wang HZ, et al. Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv 2005;2:191-197
29. Mustata G, Dinh SM. Approaches to oral drug delivery for challenging molecules. Crit Rev Ther Drug Carrier Syst 2006;23:111-135
30. Mlynek GM, Calvo LJ, Robinson JR. Carrier-enhanced human growth hormone absorption across isolated rabbit intestinal tissue. Int J Pharm 2000;197:13-21
31. Wu SJ, Robinson JR. Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone. Pharm Res 1999;16:1266-1272
32. Karsdal MA, Byrjalsen I, Azria M, et al. Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br J Clin Pharmacol 2009;67:413-420
33. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin. BMC Clin Pharmacol 2008;8:5
34. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin Pharmacol 2008;8:12
35. Karsdal MA, Byrjalsen I, Henriksen K, et al. A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin. J Clin Pharmacol 2009;49:229-234
36. Karsdal MA, Byrjalsen I, Henriksen K, et al. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy. Eur J Clin Pharmacol 2010;66:29-37
37. Ikegame M, Ejiri S, Ozawa H. Calcitonin-induced change in serum calcium levels and its relationship to osteoclast morphology and number of calcitonin receptors. Bone 2004;35:27-33
38. Chesnut CH III, Majumdar S, Newitt DC, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res 2005;20:1548-1561
39. Jiang Y, Zhao J, Geusens P, et al. Femoral neck trabecular microstructure in ovariectomized ewes treated with calcitonin: MRI microscopic evaluation. J Bone Miner Res 2005;20:125-130
40. Karsdal MA, Henriksen K, Arnold M, Christiansen C. Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 2008;22:137-144
41. Hattner R, Epker BN, Frost HM. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 1965;206:489-490
42. Takahashi H, Epker B, Frost HM. Resorption precedes formative activity. Surg Forum 1964;15:437-438
43. Sarnsethsiri P, Hitt OK, Eyring EJ, Frost HM. Tetracycline-based study of bone dynamics in pycnodysostosis. Clin Orthop Relat Res 1971;74:301-312
44. Henriksen K, Tanko LB, Qvist P, et al. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 2007;18:681-685
45. Karsdal MA, Qvist P, Christiansen C, Tanko LB. Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression? Drugs 2006;66:1909-1918
46. Martin TJ, Seeman E. New mechanisms and targets in the treatment of bone fragility. Clin Sci (Lond) 2007;112:77-91
47. Karsdal MA, Henriksen K. Osteoclasts control osteoblast activity, IBMS BoneKEy 2007;4:19-24
48. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999;24:237-244
49. Hwang JS, Tu ST, Yang TS, et al. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 2006;17:373-378
50. Schlemmer A, Hassager C, Jensen SB, Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 1992;74:476-480
51. Gertz BJ, Clemens JD, Holland SD, et al. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 1998;63:102-106
52. Qvist P, Christgau S, Pedersen BJ, et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002;31:57-61
53. Azria M. The calcitonins. Physiology and pharmacology. Basel: Karger; 1989
54. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Bone Miner Res 2009;24(Suppl 1). Available from: http:// www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail. aspx? aid=2167c9c3-703f-43d8-b76ba35dcf86d465 [Last accessed 28 October 2010]
55. Eisman J, Bone H III, Hosking D Jr. Odanacatib in the treatment of postmenopausal women with low bone mineral density: long-term continued therapy and resolution of effect. J Bone Miner Res 2009;24(Suppl 1). Available from: http://www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail.aspx? aid=645701ba-5b42-46a4-b3cf-4657bf92fb94 [Last accessed 28 October 2010]
56. Cummings SR, San MJ, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765
57. Bone HG, McClung MR, Roux C, et al. 10/29/2009 odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2009;24(Suppl 1). Available from: http:// www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail.aspx? aid=645701ba-5b42- 46a4-b3cf-4657bf92fb94 [Last accessed 28 October 2010]
58. Henriksen K, Sorensen MG, Nielsen RH, et al. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification. J Bone Miner Res 2006;21:58-66
59. Kiviranta R, Morko J, Alatalo SL, et al. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 2005;36:159-172
60. Overgaard K, Hansen MA, Nielsen VA, et al. Discontinuous calcitonin treatment of established osteoporosis-effects of withdrawal of treatment. Am J Med 1990;89:1-6
61. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005;11:76-81
62. Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001;69:281-286
63. Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 1998;44:2290-2300
64. Burr DB. Targeted and nontargeted remodeling. Bone 2002;30:2-4
65. Viguet-Carrin S, Garnero P, Delmas PD. The role of collagen in bone strength. Osteoporos Int 2006;17:319-336
66. Byrjalsen I, Leeming DJ, Qvist P, et al. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int 2008;19:339-348
67. Karsdal MA, Byrjalsen I, Leeming DJ, et al. The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int 2008;19:1355-1361
68. Leeming DJ, Henriksen K, Byrjalsen I, et al. Is bone quality associated with collagen age? Osteoporos Int 2009;20:1461-1470
69. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:1185-1194
70. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-276
71. Compston J Over-suppression of bone turnover: does it exist? Curr Osteoporos Rep 2007;5:179-185
72. Watts NB, Diab DL. Long-term use of bisphosphosphonates in osteoporosis. J Clin Endocrinol Metab 2010: published online 19 February 2010, doi:10.1210/jc.2009-1947
73. Dobnig H, Stepan JJ, Burr DB, et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 2009;24:1998-2006
74. Jung TI, Hoffmann F, Glaeske G, Felsenberg D. Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy. J Cancer Res Clin Oncol 2010;136:363-370
75. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362:1761-1771
76. Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 2010;362:1825-1827
77. Knopp JA, Diner BM, Blitz M, et al. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 2005;16:1281-1290
78. Blau LA, Hoehns JD. Analgesic efficacy of calcitonin for vertebral fracture pain. Ann Pharmacother 2003;37:564-570
79. Gabopoulou Z, Vadalouca A, Velmachou K, et al. Epidural calcitonin: does it provide better postoperative analgesia? An analysis of the haemodynamic, endocrine, and nociceptive responses of salmon calcitonin and opioids in epidural anesthesia for hip arthroplasty surgery. Pain Pract 2002;2:326-331
80. Ofluoglu D, Akyuz G, Unay O, Kayhan O. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol 2007;26:44-49
81. Pecile A. Calcitonin and relief of pain. Bone Miner 1992;16:187-189
82. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-3617
83. Gennari C. Analgesic effect of calcitonin in osteoporosis. Bone 2002;30:67S-70S
84. Lyritis GP, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 1991;49:369-372
85. Lyritis GP, Paspati I, Karachalios T, et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 1997;275:112-114
86. Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 1999;15:284-289
87. Kessel C, Worz R. Immediate response of phantom limb pain to calcitonin. Pain 1987;30:79-87
88. Jaeger H, Maier C. Calcitonin in phantom limb pain: a double-blind study. Pain 1992;48:21-27
89. Zieleniewski W. Calcitonin nasal spray for painful diabetic neuropathy. Lancet 1990;336:449
90. Appelboom T. Calcitonin in reflex sympathetic dystrophy syndrome and other painful conditions. Bone 2002;30:84S-86S
91. Gobelet C, Waldburger M, Meier JL. The effect of adding calcitonin to physical treatment on reflex sympathetic dystrophy. Pain 1992;48:171-175
92. Waldburger M, Meier JL, Gobelet C. The frozen shoulder: diagnosis and treatment. Prospective study of 50 cases of adhesive capsulitis. Clin Rheumatol 1992;11:364-368
93. Sileghem A, Geusens P, Dequeker J. Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis. Ann Rheum Dis 1992;51:761-764
94. Lyritis GP, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 1991;49:369-372
95. Lyritis GP, Paspati I, Karachalios T, et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 1997;275:112-114
96. Martinez-Zapata MJ, Roque M, Alonso-Coello P, Catala E. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev 2006;3:CD003223
97. Braga PC, Dal SM, Bernini A, et al. Antinociceptive activity of salmon calcitonin: electrophysiological correlates in a rat chronic pain model. Neurosci Lett 1993;151:85-88
98. Ustdal M, Dogan P, Soyuer A, Terzi S. Treatment of migraine with salmon calcitonin: effects on plasma beta-endorphin, ACTH and cortisol levels. Biomed Pharmacother 1989;43:687-691
99. Gennari C, Chierichetti MS, Gonnelli S, et al. Migraine prophylaxis with salmon calcitonin: a cross-over double-blind, placebo-controlled study. Headache 1986;26:13-16
100. Altman RD, Collins-Yudiskas B. Synthetic human calcitonin in refractory Paget's disease of bone. Arch Intern Med 1987;147:1305-1308
101. Miralles FS, Lopez-Soriano F, Puig MM, et al. Postoperative analgesia induced by subarachnoid lidocaine plus calcitonin. Anesth Analg 1987;66:615-618
102. Gabopoulou Z, Vadalouca A, Velmachou K, et al. Epidural calcitonin: does it provide better postoperative analgesia? An analysis of the haemodynamic, endocrine, and nociceptive responses of salmon calcitonin and opioids in epidural anesthesia for hip arthroplasty surgery. Pain Pract 2002;2:326-331
103. Pagani F, Netti C, Guidobono F, et al. Effects of amylin and salmon calcitonin on beta-endorphin-induced growth hormone and prolactin secretion in the rat. Neuroendocrinology 1998;68:220-228
104. Maeda Y, Yamada K, Hasegawa T, et al. Relationship between anti-aversive effects of salmon calcitonin and plasma levels of ACTH, beta-endorphin and prostaglandin E2 in mice. Res Commun Chem Pathol Pharmacol 1994;83:15-24
105. Rohner J, Planche D. Mechanism of the analgesic effect of calcitonin evidence for a twofold effect: morphine-like and cortisone-like. Clin Rheumatol 1985;4:218-219
106. Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 1991;49(Suppl 2):S9-13
107. Karsdal MA, Leeming DJ, Dam EB, et al. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 2008;16:638-646
108. Kwan TS, Lajeunesse D, Pelletier JP, Martel-Pelletier J. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 2010;24:51-70
109. Hayami T, Pickarski M, Wesolowski GA, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004;50:1193-1206
110. Qvist P, Christiansen C, Karsdal MA, et al. Application of biochemical markers in development of drugs for treatment of osteoarthritis. Biomarkers 2010;15:1-19
111. Karsdal MA, Byrjalsen I, Henriksen K, et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage 2010;18:150-159
112. Sondergaard BC, Wulf H, Henriksen K, et al. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage 2006;14:759-768
113. Sondergaard BC, Madsen SH, Segovia-Silvestre T, et al. Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes. BMC Musculoskelet Disord 2010;11:62
114. Purdue BW, Tilakaratne N, Sexton PM. Molecular pharmacology of the calcitonin receptor. Receptors Channels 2002;8:243-255
115. Tilakaratne N, Christopoulos G, Zumpe ET, et al. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther 2000;294:61-72
116. Young AA, Wang MW, Gedulin B, et al. Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity. Metabolism 1995;44:1581-1589
117. Edelman S, Maier H, Wilhelm K. Pramlintide in the treatment of diabetes mellitus. BioDrugs 2008;22:375-386
118. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008;68:2131-2162
119. Gattereau A, Bielmann P, Durivage J, et al. Effect of acute and chronic administration of calcitonin on serum glucose in patients with Paget's disease of bone. J Clin Endocrinol Metab 1980;51:354-357
120. Petralito A, Lunetta M, Liuzzo A, et al. Effects of salmon calcitonin on blood glucose and insulin levels under basal conditions and after intravenous glucose load. J Endocrinol Invest 1979;2:209-211
121. Passariello N, Giugliano D, Sgambato S, et al. Calcitonin, a diabetogenic hormone? J Clin Endocrinol Metab 1981;53:318-323
122. Giugliano D, Passariello N, Sgambato S, et al. Calcitonin modulation of insulin and glucagon secretion in man. Am J Physiol 1982;242:E206-13
123. Sgambato S, Passariello N, Giugliano D, D'Onofrio F. Effect of calcitonin on insulin response to arginine in man. Diabetes Metab 1979;5:213-216
124. Starke A, Keck E, Berger M, Zimmermann H. Effects of calcium and calcitonin on circulating levels of glucagon and glucose in diabetes mellitus. Diabetologia 1981;20:547-552
125. Kung AW, Pasion EG, Sofiyan M, et al. A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr Med Res Opin 2006;22:929-937
126. Manicourt DH, Azria M, Mindeholm L, Devogelaer JP. Efficacy of calcitonin therapy in patients with knee osteoarthritis: a clinical and biochemical preliminary study. Osteoarthritis Cartilage 2005;13:s88